ଉମେକ୍ଲିଡିନିଅମ

ଉମେକ୍ଲିଡିନିଅମ
Clinical data
Trade names	Incruse Ellipta
Synonyms	GSK573719A
AHFS/Drugs.com	monograph
data	EU EMA: yes;
Pregnancy; category	US: C (Risk not ruled out) ; ;
Routes of; administration	Inhalation (DPI)
Legal status
Legal status	US: ℞-only ; ℞ (Prescription only);
Pharmacokinetic data
Protein binding	~89%
Metabolism	Liver (CYP2D6)
Elimination half-life	11 hours
Excretion	Feces (58%) and urine (22%)
Identifiers
	IUPAC name Diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol bromide;
ECHA InfoCard	100.166.375
Chemical and physical data
Formula	C29H34BrNO2
Molar mass	୫୦୮.୫0 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5.[Br-];
	InChI InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1; Key:PEJHHXHHNGORMP-UHFFFAOYSA-M;

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Umeclidinium

ଉମେକ୍ଲିଡିନିଅମ, ଇନକ୍ରୁସ୍ ଏଲିପଟା ଏହାର ଏକ ବେପାର ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା କ୍ରନିକ ଅବସ୍ଟ୍ରକ୍ଟିଭ ଫୁସଫୁସ ରୋଗର (COPD) ରକ୍ଷଣାବେକ୍ଷଣ ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୨] ଏହା ଆଜ୍‌ମା ରୋଗ ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ନାହିଁ ।^[୨] ଏହି ଔଷଧ ପ୍ରଶ୍ୱାସ ସାହାଯ୍ୟରେ ଫୁସଫୁସ ଭିତରକୁ ନିଆଯାଏ । ^[୨]

ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ସ୍ୱାଦରେ ପରିବର୍ତ୍ତନ, କାଶ ଏବଂ ଆଖିରେ ଯନ୍ତ୍ରଣା ହୋଇପାରେ ।^[୨] ^[୩] ଗୁରୁତର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଆନାଫାଇଲକ୍‌ସିସ, ବ୍ରୋଙ୍କୋସ୍ପାଜ୍ମ, ମୂତ୍ର ଧାରଣ ଏବଂ ଗ୍ଲୁକୋମା ହୋଇପାରେ ।^[୨] ଯେଉଁମାନଙ୍କର କ୍ଷୀର ପ୍ରୋଟିନ୍ ଆଲର୍ଜି ଥାଏ ସେମାନଙ୍କୁ ଦେବାକୁ ଏହା ସୁପାରିଶ କରାଯାଏ ନାହିଁ ।^[୨] ଏହା ଏକ ଦୀର୍ଘକାଳ କାର୍ଯ୍ୟକାରୀ ମସ୍କାରିନିକ୍ ବିରୋଧୀ (LAMA) ଔଷଧ ।^[୨]

୨୦୧୪ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ଉମେକ୍ଲିଡିନିଅମ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୨] ଟିଓଟ୍ରୋପିଅମର ବିକଳ୍ପ ଭାବରେ ଏହାର ନାମ ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଜରୁରୀ ଔଷଧ ତାଲିକାରେ ଅଛି | ^[୪] ଯୁକ୍ତରାଜ୍ୟରେ ଏକ ମାସର ଔଷଧର ମୂଲ୍ୟ ୨୮ ପାଉଣ୍ଡ ଥିବାବେଳେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ମୂଲ୍ୟ ପ୍ରାୟ ୩୮୦ ଡଲାର ଅଟେ ।^[୩] ^[୫] ଏହା ଉମେକ୍ଲିଡିନିୟମ/ଭିଲାଣ୍ଟେରୋଲ ^[୨] ^[୬] ଏବଂ ଫ୍ଲୁଟିକାସୋନ/ଉମେକ୍ଲିଡିନିୟମ/ଭିଲାଣ୍ଟେରୋଲ ନାମରେ ମଧ୍ୟ ଉପଲବ୍ଧ ।^[୭]

ଆଧାର

↑ "Incruse Ellipta (umeclidinium inhalation powder) for Oral Inhalation Use. Full Prescribing Information" (PDF). GlaxoSmithKline, Research Triangle Park, NC 27709. Archived from the original (PDF) on 10 July 2018. Retrieved 22 February 2016.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ ^୨.୬ ^୨.୭ ^୨.୮ "Umeclidinium Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 27 January 2021. Retrieved 13 August 2021.
↑ ^୩.୦ ^୩.୧ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 263. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
↑ "Incruse Ellipta Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 29 August 2021. Retrieved 30 August 2021.
↑ Feldman GJ, Edin A (December 2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659.
↑ "TRELEGY ELLIPTA Package Insert" (PDF). GlaxoSmithKline. September 2017. Archived (PDF) from the original on 12 July 2020. Retrieved 11 July 2020.

[PI-1] "Incruse Ellipta (umeclidinium inhalation powder) for Oral Inhalation Use. Full Prescribing Information" (PDF). GlaxoSmithKline, Research Triangle Park, NC 27709. Archived from the original (PDF) on 10 July 2018. Retrieved 22 February 2016.

[AHFS2021-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ ^୨.୬ ^୨.୭ ^୨.୮ "Umeclidinium Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 27 January 2021. Retrieved 13 August 2021.

[BNF80-3] ୩.୦ ^୩.୧ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 263. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[WHO23rd-4] World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

[5] "Incruse Ellipta Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 29 August 2021. Retrieved 30 August 2021.

[6] Feldman GJ, Edin A (December 2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659.

[Trelegy_Ellipta_PI-7] "TRELEGY ELLIPTA Package Insert" (PDF). GlaxoSmithKline. September 2017. Archived (PDF) from the original on 12 July 2020. Retrieved 11 July 2020.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]